Clinical Studies On Romosozumab: An Alternative For Individuals With A High Risk Of Osteoporotic Fractures: A Current Concepts Review (Part II)
E. Carlos Rodriguez-Merchan,
Alonso Moreno-Garcia,
Hortensia De la Corte-Rodriguez
Abstract:Romosumab (ROMO) should be used to treat postmenopausal women with osteoporosis at high fracture risk after carefully considering the cardiovascular status and the risk/benefit balance. Clinicians should avoid ROMO for patients with a history of myocardial infarction or stroke in the past 12 months. Although ROMO offers an alternative for patients with a high risk of osteoporotic fractures, it is affected by previous osteoporosis treatment: using denosumab (DENO) and oral bisphosphonates for over one year atte… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.